Stay updated with breaking news from Nasdaq Lptx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leap Therapeutics (NASDAQ:LPTX – Get Free Report) had its price objective raised by analysts at HC Wainwright to $7.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 191.67% from the stock’s current price. Several other […]
Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Rating) – Analysts at HC Wainwright lowered their Q2 2023 earnings estimates for shares of Leap Therapeutics in a research report issued to clients and investors on Tuesday, May 16th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.11) per share for the quarter, down […]
Leap Therapeutics (NASDAQ:LPTX – Get Rating) and Xenetic Biosciences (NASDAQ:XBIO – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Valuation and Earnings This table compares Leap Therapeutics and […]
Mizuho reissued their buy rating on shares of Leap Therapeutics (NASDAQ:LPTX – Get Rating) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $2.00 target price on the stock. Several other analysts also recently weighed in on LPTX. HC Wainwright dropped their price objective on Leap Therapeutics […]
Leap Therapeutics (NASDAQ:LPTX – Get Rating)‘s stock had its “buy” rating reiterated by analysts at Mizuho in a research report issued on Thursday, Benzinga reports. They presently have a $2.00 price objective on the stock. Mizuho’s price objective points to a potential upside of 440.54% from the company’s current price. Several other brokerages have also […]